Eversheds Sutherland advises Azurity Pharmaceuticals on Acquisition of Sebela’s Bowel Prep Franchise
November 24, 2025
Eversheds Sutherland advises Azurity Pharmaceuticals on Acquisition of Sebela’s Bowel Prep FranchiseNovember 24, 2025 Eversheds Sutherland is pleased to have advised Azurity Pharmaceuticals on its acquisition of Sebela’s Bowel Prep Franchise, including two leading bowel preparation therapies for colonoscopies. The strategic transaction further strengthens Azurity’s commitment to serving overlooked patients by advancing access to medicines. By integrating Sebela’s bowel prep franchise, Azurity will expand its product offerings and capabilities to healthcare providers and patients in the United States. With the acquisition, Azurity welcomes more than 50 colleagues from Sebela’s commercial and support teams. Read Azurity’s press release here. The Eversheds Sutherland team was led by Partner Mike Voynich (Corporate), with support from Partner Pete Pappas (Intellectual Property), Special Counsel Anna Halsey (Intellectual Property), Senior Associate Adam Byrne (Corporate) and Associate Haley Klass (Corporate). Key contacts
Latest Insights
Latest NewsLatest Events
firm news October 26, 2026 Eversheds Sutherland deepens fintech and regulatory bench with double partn... firm news October 20, 2026 Eversheds Sutherland expands global disputes platform deal alerts October 16, 2026 Eversheds Sutherland advised Dtech on Hong Kong IPO client news October 14, 2026 Eversheds Sutherland advises on the acquisition of The Lake Como EDITION hybrid Europe Action Week 2026 Europe Action Week returns this November with a dynamic mix of events designed to help you navigate what’s next. virtual French employment law training November 03, 2026 2pm - 5pm (GMT) Virtual virtual Dutch employment law training November 10, 2026 2.00pm - 5.00pm (GMT) Virtual virtual Strategic absence management November 11, 2026 9.30am - 12.30pm (GMT) Virtual |